

GREG WALDEN
CHAIRMAN

FRANK PALLONE, JR.
RANKING MEMBER

ONE HUNDRED FIFTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE

2125 Rayburn House Office Building
Washington, D.C. 20515
Majority (202) 225-2927
Minority (202) 225-3641

April 23, 2018

Committee on Energy and Commerce
Subcommittee on Health
MARKUP NOTICE

The Subcommittee on Health will meet in open markup session on Wednesday, April 25, 2018, at 1:00 p.m., in 2123 Rayburn House Office Building to consider the following:

Controlled Substance Act

1. H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act;
2. H.R. 5041, Safe Disposal of Unused Medication Act;
3. H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018;
4. H.R. 5483, Special Registration for Telemedicine Clarification Act of 2018;
5. H.R. _____, Improving Access to Remote Behavioral Health Treatment Act of 2018;

Public Health Service Act

6. H.R. 449, Synthetic Drug Awareness Act of 2017;
7. H.R. 3545, Overdose Prevention and Patient Safety Act;
8. H.R. 3692, Addiction Treatment Access Improvement Act of 2017;
9. H.R. 4284, Indexing Narcotics, Fentanyl, and Opioids Act of 2017;
10. H.R. 4684, Ensuring Access to Quality Sober Living Act of 2017;
11. H.R. 5002, ACE Research Act;
12. H.R. 5009, Jessie's Law;
13. H.R. 5102, Substance Use Disorder Workforce Loan Repayment Act of 2018;
14. H.R. 5176, Preventing Overdoses While in Emergency Rooms Act of 2018;
15. H.R. 5197, Alternatives to Opioids (ALTO) in the Emergency Department Act;
16. H.R. 5261, TEACH to Combat Addiction Act of 2018;
17. H.R. 5272, Reinforcing Evidence-Based Standards Under Law in Treating Substance Abuse Act of 2018;

18. H.R. 5327, Comprehensive Opioid Recovery Centers Act 2018;
19. H.R. 5329, Poison Center Network Enhancement Act of 2018;
20. H.R. 5353, Eliminating Opioid-Related Infectious Diseases Act of 2018;
21. H.R. ____, To enhance and improve state-run prescription drug monitoring programs;
22. H.R. ____, To improve fentanyl testing and surveillance;
23. H.R. ____, To support the peer support specialist workforce;

Medicare Part B

24. H.R. 3331, To amend title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology;
25. H.R. ____, CMS Action Plan;
26. H.R. ____, Welcome to Medicare;
27. H.R. ____, Adding Resources on Non-Opioid Alternatives to the Medicare Handbook;
28. H.R. ____, Post-Surgical Injections as an Opioid Alternative;
29. H.R. ____, Alternative Payment Model for Treating Substance Use Disorder;
30. H.R. ____, Use of Telehealth to Treat Opioid Use Disorder;
31. H.R. ____, Incentivizing Non-Opioid Drugs;

Medicare Part D

32. H.R. 3528, Every Prescription Conveyed Securely Act;
33. H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018;
34. H.R. ____, Mandatory Lock-In;
35. H.R. ____, Beneficiary Education;
36. H.R. ____, Evaluating Abuse Deterrent Formulations;
37. H.R. ____, Prescriber Notification;
38. H.R. ____, Prescriber Education;
39. H.R. ____, Medication Therapy Management (MTM) Expansion;
40. H.R. ____, CMS/Plan Sharing;

Medicaid

41. H.R. 1925, At-Risk Youth Medicaid Protection Act of 2017;
42. H.R. 3192, CHIP Mental Health Parity Act;
43. H.R. 4005, Medicaid Reentry Act;
44. H.R. 4998, Health Insurance for Former Foster Youth Act;
45. H.R. 5477, Rural Development of Opioid Capacity Services Act;
46. H.R. 5562, To require the Secretary of Health and Human Services to develop a strategy implementing certain recommendations relating to the Protecting Our Infants Act of 2015, and for other purposes;
47. H.R. ____, Limited repeal of the IMD Exclusion for adult Medicaid beneficiaries with substance use disorder;
48. H.R. ____, Medicaid Pharmaceutical Home Act;
49. H.R. ____, Medicaid DRUG Improvement Act;
50. H.R. ____, Medicaid PARTNERSHIP Act;

51. H.R. ____, Incentives to Create Medicaid Health Homes to Treat Substance Use Disorder;
52. H.R. ____, Medicaid IMD ADDITIONAL INFO Act;
53. H.R. ____, Medicaid Graduate Medical Education Transparency Act;
54. H.R. ____, HUMAN CAPITAL in Medicaid Act;
55. H.R. ____, Require Medicaid Programs to Report on All Core Behavioral Health Measures;
56. H.R. ____, To amend title XIX of the Social Security Act to provide for Medicaid coverage protections for pregnant and postpartum women while receiving inpatient treatment for a substance use disorder;

Federal Food, Drug, and Cosmetic Act

57. H.R. 5228, Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act;
58. H.R. 5554, To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs;
59. H.R. ____, FDA and International Mail;
60. H.R. ____, 21st Century Tools for Pain and Addiction Treatments;
61. H.R. ____, FDA Opioid Sparing;
62. H.R. ____, FDA Packaging and Disposal;
63. H.R. ____, FDA Long-term Efficacy; and
64. H.R. ____, FDA Misuse/Abuse.

In keeping with Chairman Walden's announced policy, Members must submit any amendments they may have two hours before they are offered during this markup. Members may submit amendments by email to peter.kielty@mail.house.gov. Any information with respect to an amendment's parliamentary standing (e.g., its germaneness) should be submitted at this time as well.

A link to the items under consideration and the Majority Memorandum is included (<https://docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=108241>).

All amendments should be drafted to these versions. If you have any questions concerning this markup, please contact Paul Edattel at (202) 225-2927.

By Order of Chairman Burgess